Developing models of cholangiocarcinoma to close the translational gap in cancer research

References

• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–588.
   PubMed Web of Science ®Google Scholar
• Wong MCS, Jiang JY, Goggins WB, et al. International incidence and mortality trends of liver cancer: a global profile. Scientific Reports. 2017;7(1):45846. .
   PubMed Web of Science ®Google Scholar
• Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020;126(11):2666–2678. .
   PubMed Web of Science ®Google Scholar
• Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver International. 2019;39(S1):98–107. .
   PubMed Web of Science ®Google Scholar
• Rizvi S, Gores GJ. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–1229.
   PubMed Web of Science ®Google Scholar
• Simile MM, Bagella P, Vidili G, et al. Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials. Medicina (Kaunas). 2019 8;55(2):42.
   Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 2020;21(6):796–807. .
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology. 2020;21(5):671–684. .
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–114. .
   PubMed Web of Science ®Google Scholar
• Barner-Rasmussen N, Pukkala E, Jussila A, et al. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol. 2020;55(1):74–81. .
   PubMed Web of Science ®Google Scholar
• Lorenzini S, Bird TG, Boulter L, et al. Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut. 2010;59(5):645–654. .
   PubMed Web of Science ®Google Scholar
• Boulter L, Guest RV, Kendall TJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. Journal of Clinical Investigation. 2015;125(3):1269–1285. .
   PubMed Web of Science ®Google Scholar
• Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):63–78.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang H, Wan L, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020;73(5):1118–1130.
   PubMed Web of Science ®Google Scholar
• Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver flukeg-associated cholangiocarcinoma. Nat Genet. 2012;44(6):690–693.
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116–1135.
   PubMed Web of Science ®Google Scholar
• Chan-On W, Nairismägi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45(12):1474–1478.
   PubMed Web of Science ®Google Scholar
• Goyal L, Govindan A, Sheth RA, et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild‐Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015;20(9):1019–1027.
   PubMed Web of Science ®Google Scholar
• Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45(8):1630–1638.
   PubMed Web of Science ®Google Scholar
• Tariq N, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res. 2019;11:2623–2642.
   PubMed Web of Science ®Google Scholar
• Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39:7–18.
   PubMed Web of Science ®Google Scholar
• Malenica I, Donadon M, Lleo A. Molecular and Immunological Characterization of Biliary Tract Cancers: a Paradigm Shift Towards a Personalized Medicine. Cancers (Basel). 2020;12:2190.
   Web of Science ®Google Scholar
• Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9:1–23.
   Web of Science ®Google Scholar
• Xue TC, Zhang BH, Ye SL, et al. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis. Tumor Biol. 2015;36:5891–5899.
   PubMed Web of Science ®Google Scholar
• Boulter L, Guest RV, Kendall TJ, et al. WNT signalling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Investig. 2014;125:1269–1285.
   Web of Science ®Google Scholar
• Zender S, Nickeleit I, Wuestefeld T, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell. 2013;23:784–795.
   PubMed Web of Science ®Google Scholar
• Guest RV, Boulter L, Dwyer BJ, et al. Notch3 drives development and progression of cholangiocarcinoma. Proc Natl Acad Sci. 2016;113:12250–12255.
   PubMed Web of Science ®Google Scholar
• Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005;42:1329–1338.
   PubMed Web of Science ®Google Scholar
• Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144:829–840.
   PubMed Web of Science ®Google Scholar
• R V G, Boulter L, Dwyer BJ, et al. Notch3 drives development and progression of cholangiocarcinoma. . Proc Natl Acad Sci. 2016;113:3–8.
   Web of Science ®Google Scholar
• Sirica AE, Zhang Z, Lai GH, et al. A novel “patient-like” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology. 2008;47(4):1178–1190.
   PubMed Web of Science ®Google Scholar
• Mancarella S, Serino G, Dituri F, et al. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. Cell Death Differ. 2020;27(8):2330–2343.
   PubMed Web of Science ®Google Scholar
• Kitagawa K, Moriya K, Kaji K, et al. Atorvastatin augments gemcitabine-mediated anti-cancer effects by inhibiting yes-associated protein in human cholangiocarcinoma cells. Int J Mol Sci. 2020;21:1–15.
   Web of Science ®Google Scholar
• Saqub H, Proetsch-Gugerbauer H, Bezrookove V, et al. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Sci Rep. 2020;10:1–13.
   PubMed Web of Science ®Google Scholar
• Dwyer BJ, Jarman EJ, Gogoi-Tiwari J, et al. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. J Hepatol. 2020;S0168-S8278(20):33771–33775.
   Google Scholar
• Yanagihara K, Kamada N, Tsumuraya M, et al. Establishment and Characterization of the Human Cholangiocarcinoma Cell Line HChol-Y1 in a Serum-Free, Chemically Defined Medium. J Natl Cancer Inst. 1985;75:29–35.
   PubMedGoogle Scholar
• Lai GH, Zhang Z, Shen XN, et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology. 2005;129:2047–2057.
   PubMed Web of Science ®Google Scholar
• Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma : dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech. 2013;292:281–292.
   Web of Science ®Google Scholar
• Method of the Year. Organoids. Nat Methods. 2017;2018(15):1.
   Google Scholar
• Modeling Development CH. Disease with Organoids. Cell. 2016;165:1586–1597.
   PubMed Web of Science ®Google Scholar
• Huch M, Knoblich JA, Lutolf MP, et al. The hope and the hype of organoid research. Dev. 2017;144:938–941.
   PubMed Web of Science ®Google Scholar
• Abdel Fattah AR, Ranga A. Nanoparticles as Versatile Tools for Mechanotransduction in Tissues and Organoids. Front Bioeng Biotechnol. 2020;8:1–12.
   PubMed Web of Science ®Google Scholar
• Simian M, Bissell MJ. Organoids: a historical perspective of thinking in three dimensions. J Cell Biol. 2017;216:31–40.
   PubMed Web of Science ®Google Scholar
• Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21(10):571–584.
   PubMed Web of Science ®Google Scholar
• Huch M, Gehart H, Van Boxtel R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015;160:299–312.
   PubMed Web of Science ®Google Scholar
• Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5 + liver stem cells induced by Wnt-driven regeneration. Nature. 2013;494:247–250.
   PubMed Web of Science ®Google Scholar
• Wu F, Wu D, Ren Y, et al. Generation of hepatobiliary organoids from human induced pluripotent stem cells. J Hepatol. 2019;70:1145–1158.
   PubMed Web of Science ®Google Scholar
• Sampaziotis F, De BMC, Madrigal P, et al. Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. . Front Bioeng Biotechnol. 2016;33:845–852.
   Google Scholar
• Prior N, Hindley CJ, Rost F, et al. Lgr5+ stem and progenitor cells reside at the apex of a heterogeneous embryonic hepatoblast pool. Dev. 2019;146.dev174557
   Web of Science ®Google Scholar
• Prior N, Inacio P, Huch M. Liver organoids: from basic research to therapeutic applications. Gut. 2019;68:2228–2237.
   PubMed Web of Science ®Google Scholar
• Sampaziotis F, Justin AW, Tysoe OC, et al. Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nat Med. 2017;23:954–963.
   PubMed Web of Science ®Google Scholar
• Ford MJ, Yeyati PL, Mali GR, et al. A Cell/Cilia Cycle Biosensor for Single-Cell Kinetics Reveals Persistence of Cilia after G1/S Transition Is a General Property in Cells and Mice. Dev Cell. 2018;47:509–523.e5.
   PubMed Web of Science ®Google Scholar
• Vyas D, Baptista PM, Brovold M, et al. Self-assembled liver organoids recapitulate hepatobiliary organogenesis in vitro. Hepatology. 2018;67:750–761.
   PubMed Web of Science ®Google Scholar
• Andersson ER, Chivukula IV, Hankeova S, et al. Mouse Model of Alagille Syndrome and Mechanisms of Jagged1 Missense Mutations. Gastroenterology. 2018;154:1080–1095.
   PubMed Web of Science ®Google Scholar
• Yang L, Han Y, Nilsson-Payant BE, et al. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell. 2020;27(1)125–136.
   PubMed Web of Science ®Google Scholar
• Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020;11(10):771–775.
   PubMed Web of Science ®Google Scholar
• Soroka CJ, Assis DN, Boyer JL. Patient-derived organoids from human bile: an in vitro method to study cholangiopathies. Methods Mol Biol. 2019;1981:363–372.
   PubMedGoogle Scholar
• Broutier L, Mastrogiovanni G, Verstegen MMA, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23:1424–1435.
   PubMed Web of Science ®Google Scholar
• Saito Y, Muramatsu T, Kanai Y, et al. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma. Cell Rep. 2019;27:1265–1276.e4.
   PubMed Web of Science ®Google Scholar
• Lampis A, Carotenuto P, Vlachogiannis G, et al. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology. 2018;154:1066–1079.
   PubMed Web of Science ®Google Scholar
• Yao Y, Xu X, Yang L, et al. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Rep. 2020;e6:17–26.
   Google Scholar
• Guo B, Li L, Guo J, et al. M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma. Oncotarget. 2017;8:44465–44476.
   PubMedGoogle Scholar
• Dijkstra KK, Cattaneo CM, Weeber F, et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 2018;174:1586–1598.e12.
   PubMed Web of Science ®Google Scholar
• Neal JT, Li X, Zhu J, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175:1972–1988.e16.
   PubMed Web of Science ®Google Scholar
• Van De Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933–945.
   PubMed Web of Science ®Google Scholar
• Amato F, Rae C, Prete MG, et al. Cholangiocarcinoma Disease Modelling Through Patients Derived Organoids. Cells. 2020;9:832.
   Web of Science ®Google Scholar
• Qin X, Sufi J, Vlckova P, et al. Cell-type-specific signaling networks in heterocellular organoids. Nat Methods. 2020;7(3):335–342.
   Web of Science ®Google Scholar
• Giobbe GG, Crowley C, Luni C, et al. Extracellular matrix hydrogel derived from decellularized tissues enables endodermal organoid culture. Nat Commun. 2019;10(1):5658.
   PubMed Web of Science ®Google Scholar
• Mollica PA, Booth-Creech EN, Reid JA, et al. 3D bioprinted mammary organoids and tumoroids in human mammary derived ECM hydrogels. Acta Biomater. 2019;95:201–213.
   PubMed Web of Science ®Google Scholar
• Verna L, Whysner J, Williams GMN. Nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther. 1996;71:57–81.
   PubMed Web of Science ®Google Scholar
• Yang H, Li TWH, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology. 2011;141:378–388.
   PubMed Web of Science ®Google Scholar
• Loeuillard E, Fischbach SR, Gores GJ, et al. Animal models of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2019;1865:982–992.
   PubMed Web of Science ®Google Scholar
• Mariotti V, Strazzabosco M, Fabris L, et al. Animal models of biliary injury and altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1254–1261.
   PubMed Web of Science ®Google Scholar
• Aller MA, Arias JL, Prieto I, et al. Bile duct ligation: step-by-step to cholangiocyte inflammatory tumorigenesis. Eur J Gastroenterol Hepatol. 2010;22:651–661.
   PubMed Web of Science ®Google Scholar
• Von Tungeln LS, Walker NJ, Olson GR, et al. Low dose assessment of the carcinogenicity of furan in male F344/N Nctr rats in a 2-year gavage study. Food Chem Toxicol. 2017;99:170–181.
   PubMed Web of Science ®Google Scholar
• Elmore LW, Sirica AE. Phenotypic Characterization of Metaplastic Intestinal Glands and Ductular Hepatocytes in Cholangiofibrotic Lesions Rapidly Induced in the Caudate Liver Lobe of Rats Treated with Furan. Cancer Res. 1991;51:5752–5759.
   PubMed Web of Science ®Google Scholar
• Maronpot RR, Giles HD, Dykes DJ, et al. Furan-induced hepatic cholangiocarcinomas in Fischer 344 rats. Toxicol Pathol. 1991;19:561–570.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Brivio S, Stecca T, et al. Animal models of cholangiocarcinoma: what they teach us about the human disease. Clin Res Hepatol Gastroenterol. 2018;42:403–415.
   PubMed Web of Science ®Google Scholar
• Becker FF. Thioacetamide hepatocarcinogenesis. J Natl Cancer Inst. 1983.71(3):553-8.
   PubMedGoogle Scholar
• Dasgupta A, Chatterjee R, Roy Chowdhury J. Thioacetamide-Induced Hepatocarcinoma in Rat. Oncology. 1981;38(4):249-53
   PubMed Web of Science ®Google Scholar
• Praet MM, Roels HJ. Histogenesis of cholangiomas and cholangiocarcinomas in thioacetamide fed rats. 1984;26(1):3-14.. Exp Pathol..
   Google Scholar
• Hajovsky H, Hu G, Koen Y, et al. Metabolism and toxicity of thioacetamide and thioacetamide S-Oxide in rat hepatocytes. Chem Res Toxicol. 2012;25:1955–1963.
   PubMed Web of Science ®Google Scholar
• Yeh CN, Maitra A, Lee KF, et al. Thioaceatamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis. 2004;25:631–636.
   PubMed Web of Science ®Google Scholar
• Sander JD, Joung JKCRISPR. Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014;32(4):347–355.
   PubMed Web of Science ®Google Scholar
• Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019 16(5):269–281
   PubMed Web of Science ®Google Scholar
• Schaub JR, Huppert KA, Kurial SNT, et al. De novo formation of the biliary system by TGFβ-mediated hepatocyte transdifferentiation. Nature. 2018;557(7704):247–251.
   PubMed Web of Science ®Google Scholar
• Raven A, Lu WY, Man TY, et al. Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration. Nature. 2017;547(7663):350–354.
   PubMed Web of Science ®Google Scholar
• Chen X, Calvisi DF. Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research. Am J Pathol. 2014;184:912–923.
   PubMed Web of Science ®Google Scholar
• Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243–3248.
   PubMed Web of Science ®Google Scholar
• Falix FA, Weeda VB, Labruyere WT, et al. Hepatic Notch2 deficiency leads to bile duct agenesis perinatally and secondary bile duct formation after weaning. Dev Biol. 2014;396(2):201–213.
   PubMed Web of Science ®Google Scholar
• El Khatib M, Bozko P, Palagani V, et al. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS One. 2013;8(10):e77433.
   PubMed Web of Science ®Google Scholar
• Benhamouche S, Curto M, Saotome I, et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 2010;24:1718–1730.
   PubMed Web of Science ®Google Scholar
• Newsome JR, Venkatramani R, Heczey A, et al. Cholangiocarcinoma among children and adolescents: a review of the literature and surveillance, epidemiology, and end results program database analysis. J Pediatr Gastroenterol Nutr. 2018;66(1):e12–e18.
   PubMed Web of Science ®Google Scholar
• Means AL, Xu Y, Zhao A, et al. A CK19CreERT knockin mouse line allows for conditional DNA recombination in epithelial cells in multiple endodermal organs. Genesis. 2008;46:318–323.
   PubMed Web of Science ®Google Scholar
• Kopp JL, Dubois CL, Schaffer AE, et al. Sox9+ ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. Development. 2011;138(4):653–665.
   PubMed Web of Science ®Google Scholar
• Jörs S, Jeliazkova P, Ringelhan M, et al. Lineage fate of ductular reactions in liver injury and carcinogenesis. J Clin Invest. 2015;125(6):2445–2457.
   PubMed Web of Science ®Google Scholar
• Xu X, Kobayashi S, Qiao W, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest. 2006;116(7):1843–1852.
   PubMed Web of Science ®Google Scholar
• Hill MA, Alexander WB, Guo B, et al.Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. 2018;4445–4452.
   Google Scholar
• Guest RV, Boulter L, Kendall TJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 2014;74(4):1005–1010.
   PubMed Web of Science ®Google Scholar
• Lannagan TR, Jackstadt R, Leedham SJ, et al. Advances in colon cancer research: in vitro and animal models. Curr Opin Genet Dev. 2021;66:50–56.
   PubMed Web of Science ®Google Scholar
• Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Ther. 2007;15:2063–2069.
   PubMed Web of Science ®Google Scholar
• Liu F, Song YK, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6:1258–1266.
   PubMed Web of Science ®Google Scholar
• Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. 1999;10:1735–1737.
   PubMed Web of Science ®Google Scholar
• Zhang G, Gao X, Song YK, et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther. 2004;11(8) 675–682.
   PubMed Web of Science ®Google Scholar
• Fan B, Chen X, Willenbring H, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Invest. 2012;122:2911–2915.
   Google Scholar
• Evert M, Dombrowski F, Ribback S, et al. On the Role of Notch1 and Adult Hepatocytes in Murine Intrahepatic Cholangiocarcinoma Development. Hepatology. 2013;58:1857–1859.
   PubMed Web of Science ®Google Scholar
• Wang J, Dong M, Xu Z, et al. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 2018; 37(24) 3229–3242.
   PubMed Web of Science ®Google Scholar
• Weber J, Öllinger R, Friedrich M, et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-Throughput functional cancer genomics in mice. Proc Natl Acad Sci U S A. 2015;112(45):13982–13987.
   PubMed Web of Science ®Google Scholar
• Gürlevik E, Fleischmann-Mundt B, Armbrecht N, et al. Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. Hepatology. 2013;58:1031–1041.
   PubMed Web of Science ®Google Scholar
• Mohr R, Özdirik B, Knorr J, et al. In vivo models for cholangiocarcinoma—What can we learn for human disease? Int J Mol Sci. 2020;21:1–15.
   Web of Science ®Google Scholar